Cargando…

Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model

INTRODUCTION: Recombinant human soluble thrombomodulin (rhsTM) is newly developed for the treatment of DIC. The purpose of this study was to evaluate the efficacy of the concomitant administration of rhsTM and antithrombin (AT). METHODS: In the first series, rats were treated with either 62.5, 125,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iba, Toshiaki, Nakarai, Etsuro, Takayama, Toshio, Nakajima, Kenji, Sasaoka, Tetsumasa, Ohno, Yoichi
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811901/ https://www.ncbi.nlm.nih.gov/pubmed/20003418 http://dx.doi.org/10.1186/cc8210

Ejemplares similares

Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin
por: Wada, Hideo, et al.
Publicado: (2023)

Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2017)

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2019)

Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki
Publicado: (2015)

Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
por: Nakayama, Satoshi, et al.
Publicado: (2020)

Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis
por: Wada, Takeshi, et al.
Publicado: (2022)

Protective Effects of Recombinant Human Soluble Thrombomodulin on Lipopolysaccharide-Induced Acute Kidney Injury
por: Nozaki, Yuji, et al.
Publicado: (2020)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced DIC
por: Yamakawa, K, et al.
Publicado: (2014)

Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis
por: Iba, Toshiaki, et al.
Publicado: (2020)

Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2014)

Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
por: Murao, Atsushi, et al.
Publicado: (2022)

Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin
por: Iba, Toshiaki, et al.
Publicado: (2018)

Recombinant Human Soluble Thrombomodulin Suppresses Monocyte Adhesion by Reducing Lipopolysaccharide-Induced Endothelial Cellular Stiffening
por: Okamoto, Takayuki, et al.
Publicado: (2020)

Clinical Efficacy of Soluble Thrombomodulin, Tissue Plasminogen Activator Inhibitor complex, Thrombin-Antithrombin complex,α2-Plasmininhibitor-Plasmin complex in Pediatric Sepsis
por: Li, Juanzhen, et al.
Publicado: (2022)

Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments
por: Hayakawa, Mineji
Publicado: (2017)

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Efficacy of recombinant human soluble thrombomodulin in disseminated intravascular coagulation
por: Yasuda, T, et al.
Publicado: (2010)

Use of Antithrombin and Thrombomodulin in the Management of Disseminated Intravascular Coagulation in Patients with Acute Cholangitis
por: Nakahara, Kazunari, et al.
Publicado: (2013)

Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients
por: Miyoshi, Seigo, et al.
Publicado: (2014)

Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation
por: Iba, Toshiaki, et al.
Publicado: (2018)

Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation
por: Morita, Nozomi, et al.
Publicado: (2018)

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2013)

Use of Recombinant Human Soluble Thrombomodulin in Patients with Sepsis-Induced Disseminated Intravascular Coagulation after Intestinal Perforation
por: Tagami, Takashi, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study
por: Kato, Takahiro, et al.
Publicado: (2018)

Recombinant human soluble thrombomodulin is associated with attenuation of sepsis-induced renal impairment by inhibition of extracellular histone release
por: Akatsuka, Masayuki, et al.
Publicado: (2020)

Markers of acute kidney injury in patients with sepsis: the role of soluble thrombomodulin
por: Katayama, Shinshu, et al.
Publicado: (2017)

Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study
por: Umemura, Yutaka, et al.
Publicado: (2018)

Coagulofibrinolytic effects of recombinant soluble thrombomodulin in prolonged porcine cardiac arrest
por: Zhang, Boya, et al.
Publicado: (2023)

A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis
por: Gando, Satoshi, et al.
Publicado: (2013)

Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura
por: Nakamura, Kensuke, et al.
Publicado: (2016)

Antithrombin in sepsis revisited
por: Levi, Marcel
Publicado: (2005)

The antithrombin activity recovery after substitution therapy is associated with improved 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2023)

The effect of antithrombin added to recombinant human-soluble thrombomodulin for severe community-acquired pneumonia-associated disseminated intravascular coagulation: a retrospective cohort study using a nationwide inpatient database
por: Suzuki, Jun, et al.
Publicado: (2020)

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yoshimura, Jumpei, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study
por: Kato, Takahiro, et al.
Publicado: (2013)

Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy
por: Levi, Marcel, et al.
Publicado: (2020)

Effectiveness of combined antithrombin and thrombomodulin therapy on in-hospital mortality in mechanically ventilated septic patients with disseminated intravascular coagulation
por: Umegaki, Takeshi, et al.
Publicado: (2020)

Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
por: Akahoshi, Tomohiko, et al.
Publicado: (2022)

Clinical efficacy of recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation
por: Suzuki, Y, et al.
Publicado: (2013)

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mopbmqanhfhgstomtssd529agu